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Abstract The myosin heavy chain (MyHC) is the molec-
ular motor of muscle and forms the backbone of the
sarcomere thick filaments. Different MyHC isoforms are of
importance for the physiological properties of different
muscle fiber types. Hereditary myosin myopathies have
emerged as an important group of diseases with variable
clinical and morphological expression depending on the
mutated isoform and type and location of the mutation.
Dominant mutations in developmental MyHC isoform genes
(MYH3 and MYH8) are associated with distal arthrogryposis
syndromes. Dominant or recessive mutations affecting the
type IIa MyHC (MYH2) are associated with early-onset
myopathies with variable muscle weakness and ophthal-
moplegia as a consistent finding. Myopathies with
scapuloperoneal, distal or limb-girdle muscle weakness
including entities, such as myosin storage myopathy and
Laing distal myopathy are the result of usually dominant
mutations in the gene for slow/b cardiac MyHC (MYH7).
Protein aggregation is part of the features in some of these
myopathies. In myosin storage myopathy protein aggregates
are formed by accumulation of myosin beneath the sarco-
lemma and between myofibrils. In vitro studies on the effects
of different mutations associated with myosin storage
myopathy and Laing distal myopathy indicate altered
biochemical and biophysical properties of the light mero-
myosin, which is essential for thick filament assembly.
Protein aggregates in the form of tubulofilamentous inclu-
sions in association with vacuolated muscle fibers are
present at late stage of dominant myosin IIa myopathy and
sometimes in Laing distal myopathy. These protein aggre-
gates exhibit features indicating defective degradation of
misfolded proteins. In addition to protein aggregation and
muscle fiber degeneration some of the myosin mutations
cause functional impairment of the molecular motor adding
to the pathogenesis of myosinopathies.
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Introduction
Myosin is a highly conserved, ubiquitous protein found in
all eukaryotic cells [57]. It acts as a molecular motor that
converts chemical energy of ATP hydrolysis into
mechanical force for diverse cellular movements such as
cytokinesis, phagocytosis, and muscle contraction [58].
Myosins constitute a diverse superfamily and are grouped
into different classes including the conventional, or class II,
two-headed myosins that form filaments in striated muscle,
smooth muscle and non-muscle cells [64]. The class II
conventional muscle myosin exists as a hexameric protein
composed of two myosin heavy chain (MyHC) subunits
and two pairs of non-identical light chain subunits [57, 64].
MyHCs associate into dimers through a coiled-coil inter-
action along its long tail, which is termed the rod domain
(Fig. 1). Dimerization of two heavy chains results in a
polar structure with two distinct regions, which provide the
motor and filament-forming functions. The amino terminus
forms a globular head domain that binds to actin and ATP,
which is required for motor activity [56]. The elongated
a-helical coiled-coil C-terminal rod domain exhibits
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filament-forming properties that assemble into thick fila-
ments of the sarcomeres (Fig. 1) [57].
Mutations in MyHC genes have been demonstrated to be
an important cause of various myopathies, some of which are
associated with protein aggregates in muscle fibers [49, 50].
Myosin heavy chain isoforms
There are several striated muscle MyHC isoforms encoded
by different genes and expressed in a tissue and develop-
mental specific manner [61–63, 84, 85]. In adult human
limb skeletal muscle there are three major MyHC isoforms:
MyHC I, also called slow/ß-cardiac MyHC, is encoded by
MYH7 and is expressed in slow, type 1 muscle fibers as
well as in the ventricles of the heart; MyHC IIa (MYH2) is
expressed in fast, type 2A muscle fibers and MyHC IIx
(MYH1) is expressed in fast, type 2B muscle fibers [66]
(Table 1). The three different muscle fiber types differ in
their contractile and physiological properties, which are
partly determined by the different MyHCs. In addition,
embryonic and perinatal MyHCs, encoded by MYH3 and
MYH8, are expressed during fetal development and also
during muscle regeneration [24, 31].
In addition to the common MyHC isoforms expressed in
fibers of adult human limb muscles, there are special MyHC
isoforms expressed in specific muscles. Muscles of the head
and neck such as the masseter muscle show a more diverse
expression of MyHC isoforms than limb muscles [52] and
very fast contracting fibers found in extraocular muscles
express extraocular MyHC isoform (MYH13) [54].
The non-muscle conventional class II MyHC genes
MYH9 and MYH10 encode the non-muscle myosins IIA
(MYHIIA) and IIB (MYHIIB), whereas MYH11 encodes
smooth muscle MyHC.
Myosin heavy chain diseases
The first striated muscle MyHC isoform associated with
disease in humans was slow/b cardiac MyHC (MYH7) [25].
Fig. 1 a Electron micrograph of a skeletal muscle sarcomere,
demonstrating thick and thin filaments and the banding pattern.
b Schematic drawing of the sarcomere demonstrating the thin
filaments composed mainly of actin, tropomyosin and the troponin
complex and the thick filaments composed mainly of myosin with the
myosin heavy chain (MyHC) globular heads interacting with the thin
filaments. c Illustration of the MyHC dimer with approximate binding
sites for ATP, actin, myosin-binding protein C, myomesin-1,
M-protein and titin. The assembly competence domain in the distal
rod region is indicated. The different regions of the MyHC (S1, S2
and light meromyosin, LMM) are indicated by different colors
Table 1 Myosin heavy chain isoforms expressed in human muscle
Protein Gene Muscle fiber type
MyHC IIx/d MYH1 Type 2B
MyHC IIa MYH2 Type 2A
Extraocular muscle
Embryonic MyHC MYH3 Fetal development
Muscle regeneration





Fetal MyHC MYH8 Fetal development
Muscle regeneration
Smooth muscle MyHC MYH11 Smooth muscle
Extraocular MyHC MYH13 Extraocular muscle
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More than 200 different dominant mutations in MYH7 have
been associated with hypertrophic and dilated cardiomy-
opathy. Mutations in slow/a-cardiac MyHC (MYH6) have
been reported to cause hypertrophic and dilated cardio-
myopathy and atrial septal defect [14, 16].
MYH9-related disorders are autosomal dominant syn-
dromes, variably affecting platelet formation, hearing, and
kidney function, and result from mutations in the human
nonmuscle myosin IIA heavy chain gene (MYH9). They
have previously been described as distinct disorders
including Sebastian, Fechtner and Epstein syndromes and
May-Hegglin anomaly [7, 27].
The first pure skeletal myopathy associated with an
identified MyHC mutation was a MyHC IIa myopathy,
associated with a dominant MYH2 mutation that was
described in 2000 [40]. Since then, mutations in genes
encoding different MyHC isoforms (MYH2, MYH3, MYH7
and MYH8) have been associated with various skeletal
muscle diseases, which are summarized in Table 2.
Loss of thick filaments and myosin, but preserved thin
filaments can be seen as an unspecific alteration in various
conditions such as dermatomyositis but more typically in
critical illness myopathy [37]. This loss of myosin and
other proteins associated with the thick filaments is fre-
quently triggered by systemic corticosteroid hormone
treatment, postsynaptic block of neuromuscular transmis-
sion and prolonged mechanical ventilation. The loss of
myosin can be identified by electron microscopy showing a
characteristic disappearance of thick filaments or by mea-
suring the ratio of myosin to actin after separation of
muscle proteins by gel electrophoresis.
Myopathies associated with developmental MyHC
isoforms, MYH3 and MYH8
The essential roles of embryonic and fetal MyHC isoforms
for normal fetal development has been highlighted by the
identification of dominant MYH3 and MYH8 mutations
associated with distal arthrogryposis (DA) syndromes. In
addition to common DA manifestations such as clubfeet
and clenched fists these syndromes frequently include also
decreased movement of proximal joints, facial dysmor-
phism and other manifestations [8, 26].
At least 18 mutations in the globular head and rod
domains of MYH3 have been associated with DA1, DA2A
(Freeman–Sheldon syndrome) and DA2B (Sheldon–Hall
syndrome) [3, 71, 79]. The amino acid at position 672
(R672) is the most frequently mutated residue associated
with Freeman–Sheldon syndrome indicating a mutational
hotspot of this residue [79]. One mutation has been identi-
fied in MYH8 in several unrelated families with the trismus-
pseudocamptodactyly syndrome [78, 82]. Interestingly, this
mutation in MYH8 affects the residue R764 (R764Q), which
is paralogous to R672 in MYH3. The embryonic and fetal
MyHCs are expressed during embryonic and fetal devel-
opment [24, 31] and it has been suggested that mutations in
MYH3 and MYH8 cause a developmental myopathy
resulting in reduced fetal movement and joint contractures
[71, 79]. There are few reports on muscle pathology in distal
arthrogryposis associated with MyHC mutations. These
reports are limited to muscle biopsies from children and
adults, which show minor unspecific changes [71].
Myopathies associated with MyHC IIa, MYH2
Dominant as well as recessive mutations in MYH2 that
cause myopathy have been identified.
Autosomal dominant MyHC IIa myopathy, which has
also been referred to as ‘‘autosomal dominant myopathy
with congenital joint contractures, ophthalmoplegia and
rimmed vacuoles’’, was originally identified as a muscle
disorder in western Sweden [19]. The disease was mapped
to chromosome 17p13.1 [39] and later demonstrated to be
caused by a heterozygous missense mutation in MYH2
encoding MyHC IIa [40]. The mutation changes the
highly conserved and negatively charged glutamate at
position 706 to the positively charged lysine (E706K).
The mutated residue is located in the SH1 helix in the
core of motor domain, which is highly conserved through
evolution.
A prenatal onset of the disease was indicated by
multiple joint contractures that were present at birth in the
majority of the patients. The joint contractures preferen-
tially involved the fingers and/or hips and generally
resolved early in childhood. Hypotonia was not a prom-
inent feature and the early development was normal.
External ophthalmoplegia was present in all patients,
ranging from a slight impairment of upward gaze in
affected children to a generalized ophthalmoparesis in
some adult cases. The muscle weakness and atrophy
predominantly involved proximal muscles of the shoulder
and pelvic girdles, and also back and hand muscles.
Atrophy of the quadriceps muscles was prominent in the
more severely affected adults. The muscle weakness was
remarkably variable. Most children and adolescents and
some adults were mildly affected, whereas some adults
had experienced progressive muscle weakness affecting
ambulation from age 30 to 50 years. While mildly
affected cases had normal serum creatine kinase (s-CK)
levels, it was slightly elevated in the family members
showing a progressive course. A fine action hand tremor
has been noticed in several cases.
Muscle pathology was highly variable, also in different
muscles of the same individual. A consistent finding was a
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predominant involvement of type 2A muscle fibers (Fig. 2). In
children and mildly affected adults the type 2A fibers were
reduced in number, frequently smaller than normal and often
demonstrating disorganization of myofibrils, similar to what is
observed in multi-mini core disease [19]. Adults with pro-
gressive course and increased s-CK levels demonstrated
dystrophic muscle pathology with increased interstitial fat and
connective tissue. The presence of rimmed vacuoles in many
fibers (Fig. 3) in the more advanced cases was the reason at
that time to consider this myopathy as a variant of hereditary
inclusion body myopathy (hIBM3). The number of rimmed
vacuoles was variable also in the severely affected cases.
These rimmed vacuoles are associated with inclusions
that stain positively for ubiquitin and sequestosome 1
(SQSM1/p62) (Fig. 4a, b). SQSM1/p62 is a component of
many disease-associated intracellular multiprotein aggregates
and a useful marker for the identification of inclusions in
sporadic inclusion body myositis [18, 47]. A few inclusions
show congophilia (Fig. 4c). Inclusions of tubulofilaments
measuring 15–21 nm in diameter are present, usually in
Table 2 Myopathies associated with mutations in skeletal muscle myosin heavy chains
Gene
Protein








Congenital, reversible joint contractures.
Ophthalmoplegia.
Mild proximal muscle weakness in childhood.
Progressive course in some adults affecting
ambulation
Rimmed vacuoles with protein aggregates,
composed of 15-20 nm tubulofilaments, in
adults with progressive course and
dystrophic muscle changes. Structural
alterations with minicores in type 2 fibers in
childhood and in mildly affected muscles of
adults. Reduced number and small type 2
fibers in some cases.
Autosomal recessive myopathy
with ophthalmoplegia
Mild to moderate muscle weakness, usually
mild facial involvement. Ophthalmoplegia
Complete absence of type 2A muscle fibers.
Variable, unspecific myopathic changes











Multiple congenital joint contractures with












Irregular structure with cores in type 1 muscle
fibers in some patients
Myosin storage myopathy
OMIM #608358
Onset from childhood to middle age.
Weakness of limb girdle, scapuloperoneal
or distal muscles. Mild weakness or severe
weakness affecting ambulation
Subsarcolemmal protein aggregates in type 1
fibers that reacts with antibodies to myosin
but not to desmin. Granular and partly
filamentous structure on EM. Myofibrillar
disarray.
Laing early-onset distal myopathy,
OMIM #160500
Usually onset of distal muscle weakness in
childhood, but may be much later. Slowly
progressive course with initial weakness of
ankle dorsiflexion and ‘‘hanging big toe’’
sign
Fiber size variability, internalized nuclei,
frequently small type 1 fibers. Dystrophic
changes may occur. Rimmed vacuoles and
protein aggregates in rare cases, either as
inclusions of 15-20 nm tubulo-filaments or
as cytoplasmic bodies. Minicores may be
frequent.
Scapuloperoneal and limb girdle
syndromes
Scapuloperoneal or limb girdle muscle
weakness without morphological features of
myosin storage








Congenital contractures of hands, feet and
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association with rimmed vacuoles (Figs. 5, 6). Intranuclear
filaments can also be observed (Fig. 7).
The severity of the disease was apparently related to the
amount of expressed MyHC IIa protein in muscle [75].
Severely affected individuals and muscles showed a large
proportion of type 2A muscle fibers, and the fibers with
rimmed vacuoles expressed MyHC IIa. Studies on the
effects of endurance training have been performed [69, 74].
An 8-week endurance training program on a stationary
exercise bicycle had no adverse effects. The peak watt and
walking speed increased, but there was no significant
increase in muscle strength or isometric endurance [69].
The training program resulted in a shift in expression from
fast to slow MyHC isoforms. There was no significant
change in the MyHC IIa expression, but frequent hybrid
fibers expressing more than one MyHC isoform were
identified [74].
Patients with recessive MyHC IIa mutations have
recently been identified. The so far published cases are
homozygous or compound heterozygous for truncating
mutations in MYH2, accompanied by complete loss of
MyHC IIa protein and absence of type 2A muscle fibers
[70]. The clinical picture was surprisingly mild with minor
or moderate generalized muscle weakness including facial
muscle weakness. A consistent finding was external oph-
thalmoplegia, which was only occasionally associated with
ptosis. Magnetic resonance imaging (MRI) of lower limb
muscles in two cases demonstrated selective involvement
of certain muscles with fatty infiltration. There was pre-
dominant involvement of medial gastrocnemius in the
lower legs, combined with predominant involvement of
the semitendinosus, gracilis and vastus lateralis muscles in
the thigh.
Muscle biopsy demonstrated in addition to complete
loss of MyHC IIa protein, unspecific myopathic changes
with fiber size variability, internalized nuclei and intersti-
tial fatty infiltration [70]. Some muscle biopsy samples
demonstrated type 1 fiber uniformity. Unlike the dominant
MyHC IIa myopathy, no rimmed vacuoles or protein
aggregates have been identified.
Myopathies associated with slow/beta MyHC, MYH7
Overall, mutations in MYH7 are predominantly missense
mutations located in the globular myosin head, potentially
affecting the binding sites for actin or nucleotides but there
are also numerous mutations in the rod region. More than
200 different mutations have been associated with either
hypertrophic or dilated cardiomyopathy, but there are also
pure skeletal myopathies and combination of myopathy
and cardiomyopathy.
Myosin storage myopathy
Myosin storage myopathy is a protein aggregate myopathy
associated with myosin accumulation [76]. Mutations that
cause myosin storage myopathy are located in the distal
end of the tail of slow/b cardiac MyHC, corresponding to
exons 37–40 of MYH7 (Fig. 8).
A dominant missense mutation changing the highly
conserved and positively charged arginine at position 1845
to the uncharged, aromatic tryptophan (R1845W) was the
first mutation identified in myosin storage myopathy. This
mutation has been reported in several unrelated cases indi-
cating that the C nucleotide at position 5533 is a mutational
hotspot [32, 34, 55, 65, 76]. Two additional dominant mis-
sense mutations, H1901L [10] and L1793P [22], have later
been reported to cause myosin storage myopathy. Recently,
a heterozygous A to G transition in exon 40 of MYH7 was
reported in several individuals of a five-generation family
[51]. The mutation is predicted to change the terminal stop
codon (TAG) to a tryptophan (W), resulting in an elongation
of the C-terminal tail region (X1936WfsX32). Another
dominant in frame deletion of the amino acid lysine at
position 1784 (K1784del) in exon 37 of MYH7 has recently
been reported in a case with myosin storage myopathy [68].
Myosin storage myopathy combined with cardiomyopathy
was reported in three siblings homozygous for a missense
mutation (E1883K), but with apparently unaffected parents
[72]. Mutations in the distal rod region of slow/b cardiac
MyHC associated with myosin storage myopathy may thus
be either dominant or recessive.
Myosin storage myopathy was first reported as a familial
myopathy with probable lysis of myofibrils in type 1 fibers
by Cancilla et al. [13]. The inclusions were described as
Fig. 2 Dominant myosin IIa myopathy. Biopsy of the deltoid muscle
of a 38-year-old man showing alterations of the type 2A fibers
(arrows). NADH-tetrazolium reductase
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hyaline bodies because of their unstructured appearance at
light microscopy [15], and the term hyaline body myopathy
was used in some subsequent case reports. After the dis-
covery that the storage material consists of mainly myosin
heavy chain immunoreactive material and that the mutated
gene is the slow/b cardiac MyHC gene, MYH7, the term
myosin storage myopathy was introduced [76] and has
been adopted and used in most subsequent reports.
The clinical manifestations are highly variable ranging
from no weakness to severe impairment of ambulation
[9, 11, 13, 15, 34, 42, 55, 59, 65, 68, 76, 81]. This vari-
ability can also be present within a family [11, 55, 81].
Onset is usually in childhood but may be much later.
Presenting signs and symptoms are often delayed motor
milestones, difficulties in climbing stairs or running and a
waddling gate. The distribution of muscle weakness is
usually proximal in upper extremities with difficulties in
lifting the arms above the shoulder level and scapular
winging has been described in many cases. In the lower
extremities a distal involvement with foot drop is common
and pseudo-hypertrophy of the calves is frequently
encountered. Apart from a scapulo-peroneal distribution of
weakness, a predominant limb-girdle weakness can be seen
in some cases [13, 15]. The course is usually slowly pro-
gressive and scoliosis sometimes supervenes [11, 68] and
some patients need assisted ventilation.
Evidence of cardiomyopathy associated with the
myopathy is usually not found. However, in one woman
with muscle weakness since age 30, hypertrophic cardio-
myopathy was diagnosed at age 51 [81]. Her 24-year-old
Fig. 3 Dominant myosin IIa myopathy. Biopsy of the quadriceps muscle of a 38-year-old man demonstrating variability of fiber size, increased
interstitial connective tissue, and frequent fibers with rimmed vacuoles. a Hematoxylin and eosin; b Gomori trichrome
Fig. 4 Dominant myosin IIa myopathy. Several muscle fibers show inclusions that are immunoreactive to antibodies against p62 (a) and
ubiquitin (b). Amyloid is present in a few inclusions as revealed by Congo staining and fluorescence microscopy with Texas red filter (c)
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daughter presented with cardiac failure already at age
3 months and was diagnosed with signs of left ventricular
non-compaction. Three severely affected siblings homo-
zygous for apparently recessive mutations had myosin
storage myopathy and hypertrophic cardiomyopathy with
cardiac failure that was lethal in two cases [72].
Magnetic resonance imaging (MRI) of muscle in myosin
storage myopathy in ten individuals from one family dem-
onstrated in the lower limbs early involvement of the biceps
femoris and semimembranosus muscles and relative sparing
of the semitendinosus in the posterior compartment of the
thigh [55]. In the distal muscles of the legs there was a pre-
dominant involvement of the medial gastrocnemius, tibialis
anterior, extensor hallucis longus and extensor digitorum
longus muscles. In the upper limbs there was a predominant
involvement of the deltoid muscle. There was no asymmetry.
Muscle biopsy demonstrates the characteristic subsarco-
lemmal accumulation of material that is slightly eosinophilic
and stains light green in trichrome but there is no NADH-
tetrazolium-reductase staining (Fig. 9). By light microscopy
the material looks completely unstructured giving it a hyaline
appearance (Fig. 10a). There is no immunoreactivity of
dystrophin, sarcoglycans or merosin in relation to the stored
material, but immunostaining of desmin and also of
ab-crystalline may show a rim of intense staining around the
stored material (Fig. 10b) [11, 55]. The stored material is
restricted to type 1 fibers and usually demonstrates myofibr-
illar ATPase activity and immunoreactivity to slow/b cardiac
MyHC (Fig. 10c) [11, 51, 55, 68, 76, 81]. However, there are
also reports indicating that the accumulated material may
be immunoreactive to antibodies against fast myosin iso-
forms [15, 65]. We have found the stored material to be
Fig. 5 Dominant myosin IIa myopathy. Electron microscopy reveals
a filamentous inclusion (arrow) associated with a rimmed vacuole
with degradation products
Fig. 6 Dominant myosin IIa myopathy. Electron microscopy dem-
onstrating an inclusion composed of 15–20 nm tubulofilaments
Fig. 7 Electron micrograph illustrating intranuclear filaments
(arrow) in dominant myosin IIa myopathy
Fig. 8 Mutation in MYH7 associated with myosin storage myopathy.
They are all located in the distal rod region of the MyHC
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immunoreactive with antibodies against ubiquitin (Fig. 10d),
which is different from a previous report [11], but we have not
identified any p62 positive material. The stored material
shows no cytochrome c oxidase or succinate dehydrogenase
activity (Fig. 11a), but there is usually a rim of increased
enzyme activity in the periphery corresponding to mito-
chondria (Fig. 11b). The inclusion bodies are not limited by a
membrane but the stored material can be seen between partly
disintegrated myofibrils in the vicinity of the main storage
body (Figs. 11b, 12a). At higher magnification the storage
material has a granular appearance and a few abortive fila-
ments can be seen (Fig. 12b). The inclusions in myosin
storage myopathy differ from those in cap disease as the latter
contain remnants of sarcomeres with thickened and frag-
mented Z-lines and thin filaments. The caps show positive
immunostaining to desmin whereas the inclusions in myosin
storage myopathy are unstained.
Laing (Gowers–Laing) distal myopathy
Most patients reported with Laing distal myopathy have
dominant mutations in MYH7 located in exon 32-36 in the
mid region of the MyHC rod including: R1500P, E1508del,
L1591P, A1603P, K1617del, A1663P, L1706P and
K1729del (Fig. 13) [21, 43, 44, 80]. The L1729del muta-
tion has been identified in multiple unrelated patients
[44, 45]. However, MYH7-associated distal myopathy is
not restricted to mutations in this region. Three mutations
have been identified in the globular head (T441M, V606M
and R783P) [20, 29, 53], and three mutations have been
identified in the distal rod region overlapping with the
myosin storage myopathy region (E1801K, E1856K and
K1784del) (Fig. 13) [77, 80]. Five of these six mutations
were associated with distal myopathy and cardiomyopathy.
Muscle morphology was not reported in the patients with
the three distal mutations (K1784del, E1801K and
E1856K) [77, 80] and it cannot be excluded that they were
cases of myosin storage myopathy, since the K1784del
mutation has been associated with myosin storage myop-
athy [68]. For classification of diseases, which are
associated with mutations in the LMM of slow/b cardiac
MyHC and may show clinical overlap, it is essential to
perform muscle biopsy.
Laing distal myopathy was first linked to chromosome
14q11 [35, 83], and it was later demonstrated to be caused
by mutations in MYH7 [43]. Most cases have presented
early in childhood and hence the term ‘‘early-onset’’ distal
myopathy has been used in several reports. Onset is,
however, not always in childhood but can occur with a
range from congenital to 50 years [35, 36, 41, 44, 77, 83].
The clinical course in typical cases starts with early-onset
weakness of ankle dorsiflexors and a ‘‘hanging big toe’’
sign. Calf hypertrophy may be present. During the slowly
progressive course finger extensor and neck flexion
weakness and later also proximal limb and facial muscle
weakness supervenes. Patients usually remain ambulant.
Serum CK levels are normal or moderately elevated. Car-
diac involvement is usually not a feature of Laing distal
myopathy but there are a few exceptions with diseases
associated with MYH7 mutations and presenting with distal
myopathy as well as cardiomyopathy [20, 29, 53, 80].
Muscle MRI has demonstrated early changes in the
anterior compartments of the lower leg especially the
extensor hallucis longus and tibialis anterior muscles [21,
44, 77]. Later in the course and in more severely affected
patients additional muscles in the thigh may be involved.
Fig. 9 Myosin storage myopathy. There is fatty infiltration and numerous muscle fibers with subsarcolemmal accumulation of material (arrows)
that stains faintly red by hematoxylin–eosin (a) is unstained by NADH-tetrazolium reductase (b) and stains light green in Gomori trichrome (c)
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Muscle pathology has been reported in most case
reports and more systematically in patients from a few
families [36, 44, 83]. The pathological changes are,
unlike those in myosin storage disease, variable and
unspecific. Common findings are predominance of type 1
fibers and numerous small type 1 fibers (Fig. 14),
which may appear as fiber type disproportion. Internal
nuclei are usually present and structural abnormalities,
especially minicores, in addition to mitochondrial
abnormalities are common. Muscle fiber necrosis can be
seen but is usually not conspicuous. The muscle may
show severe atrophy with fat and connective tissue
replacement. Protein aggregates are usually not seen, but
rimmed vacuoles and filamentous inclusions of the same
type as in MyHC IIa myopathy and inclusion body
myositis have been observed [41, 77]. In one case
cytoplasmic bodies and myofibrillar alterations similar
to those seen in myofibrillar myopathies were reported
[77].
Other skeletal muscle phenotypes associated
with MYH7 mutations
Although the most important skeletal muscle manifestations
of MYH7 mutations are referred to as either myosin storage
myopathy or Laing distal myopathy several cases cannot be
classified into these groups because they either do not display
distal muscle weakness or do not exhibit hyaline bodies.
Muscle biopsy of some patients with mutations that are known
to cause myosin storage myopathy may not reveal the
pathognomonic changes, but instead unspecific changes [55]
or alterations diagnostic for congenital fiber type dispropor-
tion [51]. A few patients with MYH7 mutations that otherwise
cause distal myopathy could be classified as having limb-
girdle syndrome or scapuloperoneal myopathy thus overlap-
ping with the clinical features of myosin storage myopathy
[44]. In some but not all patients with cardiomyopathy due to
MYH7 mutations, but without overt muscle weakness, cores
may be identified in skeletal muscle fibers [23].
Fig. 10 Myosin storage myopathy. The inclusions (arrows) appear unstructured in hematoxylin-eosin (a) and are surrounded by a rim of desmin
(b). The inclusions are immunoreactive with antibodies against slow/b cardiac MyHC (c) and ubiquitin (d)
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Pathogenesis
MYH3 mutations and distal arthrogryposis
A correct understanding of the cause of distal arthrogry-
posis due to MYH3 mutations would require examination of
muscle pathology during the developmental period when
MYH3 is expressed. Since MYH3 mutations associated with
distal arthtrogryposis are dominant, it may be hypothesized
that they affect muscle function during early development
through either haploinsufficiency with insufficient dosage
of a functional embryonic MyHC or a dominant negative
effect of the mutated allele. Most of the MYH3 mutations
are missense, but it is not known whether the mutant allele
is expressed. Although the hemizygous loss of MyHC
IIa expression is tolerated well in individuals with
Fig. 11 Myosin storage myopathy. The inclusions are surrounded by
a rim of increased succinate dehydrogenase activity (arrows) (a),
which corresponds to the presence of numerous mitochondria
(arrows) around but not within the inclusions as revealed by electron
microscopy (b). There is also storage material between surrounding
myofibrils (arrow heads)
Fig. 12 Myosin storage myopathy. Electron microscopy of storage
material. a The inclusions are not limited by any membrane but
instead the storage material can be seen surrounding the adjacent
myofibrils (arrows). b The storage material appears granular and
party filamentous and some glycogen particles are also present
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heterozygous MYH2 null mutations [70], the situation may
be different with embryonic MyHC, since it is a predom-
inant MyHC isoform expressed during an early period of
development. Another possibility would be that MYH3
mutations impose dominant negative effects by functional
or structural alterations as seen in dominant mutations
affecting the adult MyHC isoforms. However, studies on
disease models are needed to pinpoint the pathogenesis of
developmental myopathy caused by MYH3 mutations.
The MyHC IIa E706K mutation
The E706K mutation associated with the autosomal dom-
inant MyHC IIa myopathy has been studied at the
molecular level in different systems. The mutated residue
is situated in the SH1 helix in the core of myosin motor
domain, which is strongly conserved throughout the myo-
sin class II family. The SH1 helix plays a central role in the
conformational changes of the myosin head during the
ATP cycle.
Several studies have suggested impaired functional
properties as the primary molecular defect of the E706K
mutated MyHC protein. In vitro motility studies on myosin
IIa isolated from single muscle fibers of patients carrying
the E706K mutation clearly showed a marked reduction of
speed [38]. Furthermore, studies on the motor function of
E683K mutant myosin of Dictyostelium discoideum, which
is equivalent to the human MyHC IIa E706K mutation,
demonstrated a threefold reduction of the ATP hydrolysis
step followed by the slower acto-myosin dissociation [87].
Consequently, these effects lead to a reduced velocity of
contraction. A transgenic C. elegans was generated to
simulate MyHC IIa myopathy in order to assess the func-
tional or structural effects of the E706K mutation [73].
Worms that were null mutant for UNC-54 (encoding the
major C. elegans myosin heavy chain expressed in body
wall muscle) were partly rescued by transfection with wild
type UNC-54. Transfection with a construct encoding
UNC-54 with an E710K mutation corresponding to the
human MyHC IIa E706K mutation resulted in restored
thick filaments but completely paralyzed worms [73]. In
addition, mutations in SH1 helix of nonmuscle class II
MYHIIA, encoded by MYH9 (R702C and R705H), have
been associated with a group of inherited giant-platelet
disorders in several families [28]. Association of diseases
with mutations in SH1 helix of myosin in both muscle and
non-muscle MyHC illustrates the crucial role of this thiol
region in the head of myosin for proper function of the
protein. These different studies all point to a severe defect
of the molecular motor function caused by the E706K
mutation.
Structural changes in the muscle fibers and muscle fiber
loss are likely to be an additional mechanism causing
Fig. 13 Mutations in MYH7 associated with distal myopathy. They
are mainly located in mid-rod region of the MyHC, but some are
located in the globular myosin head and the distal rod
Fig. 14 Tibialis anterior muscle of a 7-year-old boy with MYH7-associated distal myopathy. Many of the type 1 fibers are small (arrows).
a Myofibrillar ATPase, pH 4.3 and b NADH-tetrazolium reductase
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muscle weakness. Morphological studies on muscle biopsy
specimens have demonstrated a clear correlation between
the expression of the mutated MyHC IIa and dystrophic
changes in muscle [75]. The high expression of mutant
protein combined with aging may cause defective elimi-
nation of misfolded proteins, resulting in accumulation of
protein aggregates and secondary muscle fiber degenera-
tion. This hypothesis is supported by the accumulation of
ubiquitinated and p62-labeled protein aggregates in vacu-
olated muscle fibers. This mechanism could be similar to
what is seen in inclusion body myositis although the
upstream events are different [6, 46, 47]. The same
mechanism could also be involved in the muscle degen-
eration and protein aggregation seen in advanced cases of
Laing distal myopathy.
In a recent investigation of the molecular background of
the mouse mutant ariel a recessive missense mutation,
L342Q, in the motor domain of Myh4 was found to cause a
myofibrillar myopathy-like phenotype with protein aggre-
gates in fast MyHC IIb fibers [33]. The mutant protein
formed also aggregates in COS7 cells and did not incor-
porate into thick filaments of C2C12 cells. In ariel
heterozygotes, which showed no weakness or aggregates,
the level of mutant protein was only 7 %, indicating effi-
cient degradation of the defective protein prohibiting
protein aggregation. MYH4 is not expressed in human limb
muscle. However, mRNA but not protein has been identi-
fied in human masseter muscle [30]. A functional
equivalent of mouse MyHC IIb is MyHC IIx (MYH1) in
humans. So far no disease has been associated with human
MYH1 mutations. Protein aggregation with features similar
to those in myofibrillar myopathy and in the ariel mouse
was identified in one patient with a mutation in the rod
region of MyHC I (MYH7) mutation [77].
MyHC IIa null mutations
The selective muscle involvement of certain muscles with
fatty infiltration and loss of type 2A muscle fibers with
interstitial fatty infiltration in patients with MyHC IIa null
myopathy indicate that complete loss of one adult MyHC
cannot be compensated for by other MyHC isoforms [70].
This is further supported by studies on strains of mice null for
different MyHC isoforms indicating that different isoforms
of MyHC are functionally unique and cannot substitute for
one another [1, 2, 60]. Mice MyHC IIb or IId null strains are
viable but exhibit growth and muscle defects with significant
decreases in body mass and mean muscle mass. Although
both strains showed evidence of skeletal muscle pathology,
the extent and the pattern of affected muscles did not cor-
relate with the abundance and distribution of the two MyHC
isoforms in normal mice. Together these observations indi-
cate that MyHC isoforms impose unique structural and
functional roles and support the hypothesis that MyHC iso-
forms are unable to replace one another.
Mutations in the LMM region of slow/b-cardiac MyHC
Mutations in the middle and distal part of the slow/b-car-
diac MyHC rod (LMM) region have been associated with
several distinct morphological and clinical phenotypes
depending on the location of the mutated residue. The
assembly of MyHC filaments involves both the proper
folding of a-helices into coiled-coils, and the assembly of
these coiled-coils into filaments. Defects in any of these
steps, caused by mutations, may result in improper filament
formation leading to pathological conditions. Coiled-coils
are two-stranded protein motifs, where each strand is an
a-helix with seven-residue repeats (a–b–c–d–e–f–
g) (Fig. 15). This heptad repeat generally has apolar resi-
dues at the a and d positions. When the two a-helical
strands wrap around one another, the a and d positions are
internalized and stabilize the structure. Positions b, c, e, f, g
are exposed on the surface of the protein, where the side
chains are available to interact with other proteins, and they
may also form intra- and interchain associations that can
further stabilize the structure.
Mutations in the LMM region can affect the ability of
the protein to form stable and functional thick filaments,
based on the amino acid change, the position in the heptad
repeat motif and the location in the LMM. Missense
mutations associated with myosin storage myopathy
(L1793P, R1845W, E1883K and H1901L) are located
within or closed to the 29-residue assembly competence
domain, in the C-terminus coiled-coil rod region of MyHC,
which is known to be critical for the proper assembly of
sarcomeric myosin rod filaments [67]. These mutated res-
idues are located either in the outer b or f position, where
the side chains are available to interact with other myosin
dimers or other proteins, or in the d position that stabilize
the structure of the protein. Mutations at outer positions
may cause improper filament formation through disturbed
interaction with other myosin dimers and thereby perturb
thick filament assembly.
A disturbed interaction with other sarcomeric proteins
such as titin, myosin-binding proteins (MyBP) C and H,
M-protein or myomesin 1, may also be considered. In this
context it is of interest to note that one patient with a mutation
in the rod region of MyHC I showed cytoplasmic bodies [77],
a type of protein aggregates that are otherwise typically
associated with A-band titin (TTN) mutations [48].
The aberrant accumulations of myosin in the muscle
fibers of affected individuals with myosin storage myopa-
thy might be due to improper incorporation of mutated
myosin into thick filaments or disassembly of the filaments
resulting in accumulation of mutant protein between the
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myofibrils and beneath the sarcolemma. The observation
that some of the accumulated myosin appears to be ubiq-
uitinated indicates that it is marked to be degraded through
the proteasomal pathway [17]. The accumulation may be
due to insufficient degradation. It is noteworthy that the
inclusion bodies are not labeled by p62, which is otherwise
common in protein aggregate diseases [86].
Several in vitro studies have been performed to inves-
tigate molecular mechanisms involved in the pathogenesis
of diseases caused by mutations in the rod region of muscle
MyHC. Biochemical and biophysical characterization of
the effects of the myosin storage myopathy mutations in
the LMM region have suggested adverse effects of the
mutations in the ability of the protein to form stable and
functional thick filaments [4]. However, analyses of dif-
ferent mutations demonstrated that each mutation has a
unique effect on the biochemical and biophysical proper-
ties of the LMM [4]. The pathogenic mechanisms of the
R1500P and L1706P causing Laing early-onset distal
myopathy have been investigated by biochemical assays
and in different cellular systems [5, 12]. By co-expression
of wild-type and mutant proteins in non-muscle COS-7
cells, in the C2C12 mouse muscle cell line and in neonatal
rat ventricular myocytes, dominant adverse effects could be
demonstrated including formation of myosin aggregates
[12]. Generation of transgenic C. elegans indicated that the
proline mutations did not affect the thick filament forma-
tion or muscle force generation but myosin aggregates
were identified in the R1500P mutants [12].
It is still unclear why Laing distal myopathy and myosin
storage myopathy are associated with different muscle
pathologies. Myosin storage myopathy mutations are
located in exons 37–40 in the LMM region of slow/b-
cardiac MyHC within or close to the assembly competence
domain, which is crucial for proper filament assembly.
Consequently, mutations in this region may cause defective
integration of dimers into the thick filament leading to
accumulation of unassembled MyHC. In contrast, muta-
tions associated with Laing distal myopathy that are
situated at distance from the assembly competence domain
might cause other effects on the thick filament structure
and function leading to different pathology.
Conclusions
Further work is needed to get insight into the mechanisms
governing the cardiac and/or skeletal muscle involvement
as well as the pathogenesis leading to protein aggregation
in some of the myosin myopathies. For this purpose and for
classification of the diseases, which may show clinical
overlap, it is essential to perform morphological investi-
gations. Based on correlations between genotype and
muscle phenotype in humans, the use of animal models in
combination with in vitro studies will allow investigation
of the disease mechanisms and clarify the functional
impact of mutations affecting different isoforms and dif-
ferent domains of the MyHC.
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